Autopsy report · NCT07090369

Phase Ib Trial of 177Lu-PSMA-I&T Therapy in Combination With Olaparib and Pembrolizumab in Patients With Metastatic Castration Resistant Prostate Cancer

“Funding issues”

The sponsor’s own words in the registry.

Life of this trial

• Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.

Vital statistics

Status

Withdrawn

Phase

Phase 1

Sponsor

Peter MacCallum Cancer Centre, Australia

Sponsor type

University, hospital or other

Conditions

Metastatic Castrate Resistant Prostate Cancer (mCRPC)

Interventions

Olaparib (300 mg BID); Pembrolizumab; 177Lu-PSMA-I&T

Participants

0

Sites

1

Countries

Australia

Trials that died the same way

• IRIS-BioFreedom Cohort in the IRIS-DES Registry
  “Funding issue” (93% match in meaning)
• Biodentine Partial Pulpotomy of Pulpally Exposed Primary Molars
  “technical and funding issues” (85% match in meaning)
• Cannabinoids for Taxane Induced Peripheral Neuropathy
  “Funding being sought” (81% match in meaning)
• A Clinical Trial of BMX-010 in Adult Subjects With Atopic Dermatitis
  “Funding constraints” (81% match in meaning)
• The Use of Cannabinoid Patch for Knee Osteoarthritis
  “Inadequate funding” (80% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.